Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Positive Nodes Clear all
Completed Not applicable Interventional

Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer

NCT01526486
View directory record Official record
Conditions
Melanoma, Merkel Cell Carcinoma, Squamous Cell Carcinoma, Penile Carcinoma, Urethral Carcinoma, Extramammary Paget's Disease, Scrotal Carcinoma, Anal Cancer, Vulvar Cancer, Skin Cancer, Lymphadenopathy
Interventions
Videoscopic procedure, Open, traditional approach
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Jul 22, 2026, 11:10 AM EDT
Recruiting Phase 1 Interventional

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

NCT05819892
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Paclitaxel, Carboplatin, Dostarlimab, Cisplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients

NCT00000899
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Lamivudine, Filgrastim, Stavudine, Cyclophosphamide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 22, 2026, 11:10 AM EDT
Completed No phase listed Observational

Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344

NCT00897026
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, paclitaxel, fluorescence in situ hybridization, immunohistochemistry staining method
Drug · Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

NCT00248170
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Anastrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
33 Years to 96 Years · Female only
Enrollment
4,172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
42
States / cities
Birmingham, Alabama • Huntsville, Alabama • Flagstaff, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Jul 22, 2026, 11:10 AM EDT
Active, not recruiting Not applicable Interventional

Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer

NCT02515110
View directory record Official record
Conditions
Breast Cancer, Node-positive Breast Cancer, Breast Adenocarcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ
Interventions
External Beam Radiation Therapy
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
40 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
2
States / cities
Richmond, Virginia • South Hill, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 22, 2026, 11:10 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer

NCT01515046
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Cancer
Interventions
Gemcitabine with escalating ascorbic acid
Drug
Lead sponsor
Joseph J. Cullen
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Jul 22, 2026, 11:10 AM EDT
Active, not recruiting Phase 3 Interventional Results available

The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

NCT01706939
View directory record Official record
Conditions
Squamous Cell Carcinomas
Interventions
Reduced Dose Radiation, Standard Dose Radiation, Carboplatin
Radiation · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2035
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients

NCT00841399
View directory record Official record
Conditions
Breast Cancer
Interventions
E75 + GM-CSF vaccine
Biological
Lead sponsor
COL George Peoples, MD, FACS
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
2
States / cities
Bethesda, Maryland • Windber, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jul 22, 2026, 11:10 AM EDT
Completed No phase listed Observational Results available

Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation

NCT02348684
View directory record Official record
Conditions
Node Positive Breast Cancer
Interventions
Radiation therapy groups
Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 95 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 11:10 AM EDT
Active, not recruiting Phase 2 Interventional

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

NCT04569747
View directory record Official record
Conditions
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Interventions
Pertuzumab+TRASTUZUMAB, ADJUVANT ENDOCRINE THERAPY
Combination Product · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
32
States / cities
Stamford, Connecticut • Miami, Florida • Atlanta, Georgia + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 22, 2026, 11:10 AM EDT
Recruiting Phase 2 Interventional

Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer

NCT06833502
View directory record Official record
Conditions
Breast Cancer, Node-positive Breast Cancer
Interventions
CT Scan
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 11:10 AM EDT
Withdrawn Phase 2 Interventional

Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment

NCT02287727
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer
Interventions
Laboratory Biomarker Analysis, Regorafenib
Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
3
States / cities
Buffalo, New York • Rocherster, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Jul 22, 2026, 11:10 AM EDT
Withdrawn Not applicable Interventional

Intraoperative Imaging of a PET Positive Lymph Node(s) Using 18FDG and a Dual-Mode, Hand-Held Intraoperative Imager

NCT03561324
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Imaging Beta Probe (IBP)
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 2 Interventional

Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes

NCT00007904
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, adjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
3
States / cities
Cleveland, Ohio • Mentor, Ohio • Orange, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 3 Interventional

Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer

NCT00002646
View directory record Official record
Conditions
Breast Cancer
Interventions
fenretinide, tamoxifen citrate
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
85
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT02427841
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Interventions
Fluorouracil, Gemcitabine, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Nab-paclitaxel, Therapeutic Conventional Surgery
Drug · Radiation · Other + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Jul 22, 2026, 11:10 AM EDT
Active, not recruiting No phase listed Observational

Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation

NCT04854005
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast surgery
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Hartford, Connecticut • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Not applicable Interventional

Thoracoscopy in Patients With Stage IIIA Non-Small Cell Lung Cancer

NCT00003566
View directory record Official record
Conditions
Lung Cancer
Interventions
videothoracoscopy
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
71
States / cities
Anniston, Alabama • La Jolla, California • San Diego, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jul 22, 2026, 11:10 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer

NCT03553602
View directory record Official record
Conditions
Prostate Cancer - Recurrent
Interventions
HDR Brachytherapy + EBRT + STAD
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 22, 2026, 11:10 AM EDT
Completed No phase listed Observational

Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer

NCT00965276
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer

NCT00024102
View directory record Official record
Conditions
Breast Cancer
Interventions
Standard Treatment, capecitabine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years and older · Female only
Enrollment
633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
326
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 238 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

NCT01772472
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
60
States / cities
Anchorage, Alaska • Long Beach, California • Orange, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Jul 22, 2026, 11:10 AM EDT
Completed Phase 2 Interventional Results available

A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer

NCT02159703
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
TORS, Adjuvant Radiation Therapy
Procedure · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Jul 22, 2026, 11:10 AM EDT